Creekmur Asset Management LLC Has $88,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Creekmur Asset Management LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 87.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,021 shares of the company’s stock after selling 7,428 shares during the quarter. Creekmur Asset Management LLC’s holdings in Novo Nordisk A/S were worth $88,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after buying an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC grew its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $86,000. Finally, Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $4,066,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on NVO shares. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 21st. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 2.1 %

Shares of NYSE:NVO opened at $68.00 on Wednesday. The company’s 50-day moving average price is $81.89 and its two-hundred day moving average price is $97.68. Novo Nordisk A/S has a one year low of $66.81 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $305.16 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.